FDA-cleared profile

RayStation

RaySearch Laboratories AB (publ) · Radiotherapy Planning Imaging · FDA-cleared (510(k))

RayStation 8.1, marketed as RayStation 8B, is configurable radiation therapy treatment-planning and analysis software. It imports patient images, supports contouring, image fusion, dose calculation, optimization and plan evaluation, and exports approved treatment plans with dose, structure, and image data for treatment.

Clinical role
Treatment-planning workstation used after image acquisition to create and review patient geometry, optimize beams, calculate dose, inspect two- and three-dimensional dose displays and dose-volume histograms, approve a plan, and export approved treatment objects.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
A proposed plan must be reviewed and approved by authorized, clinically qualified users before treatment. The clearance establishes substantial equivalence and manufacturer verification and validation, not independent proof of patient outcomes or suitability for a site's machines, protocols, interfaces, and commissioned beam models.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyRadiotherapy Planning Imaging · Multi-region
  • Workflow roleTreatment-planning workstation used after image acquisition to create and review patient geometry, optimize beams, calculate dose, inspect two- and three-dimensional dose displays and dose-volume histograms, approve a plan, and export approved treatment objects.
  • Required inputPatient CT data and, where used, registered PET or MR images; user-defined regions of interest, treatment-machine data, prescription and optimization objectives, and other planning parameters.
  • Output and human actionReviewed treatment plans, calculated dose distributions, structures, images, setup parameters, two- and three-dimensional plan displays, and dose-volume histograms; approved DICOM treatment objects can be exported for downstream use.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
RayStation 8.1, marketed as RayStation 8B, is configurable radiation therapy treatment-planning and analysis software. It imports patient images, supports contouring, image fusion, dose calculation, optimization and plan evaluation, and exports approved treatment plans with dose, structure, and image data for treatment.
  • Exact FDA submission
  • Checked 2026-09-02
Workflow role
Treatment-planning workstation used after image acquisition to create and review patient geometry, optimize beams, calculate dose, inspect two- and three-dimensional dose displays and dose-volume histograms, approve a plan, and export approved treatment objects.
  • Exact FDA submission
  • Checked 2026-09-02
Required input
Patient CT data and, where used, registered PET or MR images; user-defined regions of interest, treatment-machine data, prescription and optimization objectives, and other planning parameters.
  • Exact FDA submission
  • Checked 2026-09-02
Output and clinician action
Reviewed treatment plans, calculated dose distributions, structures, images, setup parameters, two- and three-dimensional plan displays, and dose-volume histograms; approved DICOM treatment objects can be exported for downstream use.
  • Exact FDA submission
  • Checked 2026-09-02
Care setting
Professional radiation oncology environments performing treatment planning, plan review, and approved-plan transfer for radiation therapy delivery.
  • Exact FDA submission
  • Checked 2026-09-02
Intended users
Clinically qualified radiation therapy staff who have received appropriate training in use of the system.
  • Exact FDA submission
  • Checked 2026-09-02
Limitations
A proposed plan must be reviewed and approved by authorized, clinically qualified users before treatment. The clearance establishes substantial equivalence and manufacturer verification and validation, not independent proof of patient outcomes or suitability for a site's machines, protocols, interfaces, and commissioned beam models.
  • Exact FDA submission
  • Checked 2026-09-02
Evidence summary
Manufacturer nonclinical verification and validation supported the 510(k). An independent hospital study found generally close agreement between measured data and RayStation's VMC++ electron Monte Carlo calculations, but did not report the software version and did not assess clinical outcomes.
  • Product family
  • Checked 2026-09-02

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Manufacturer nonclinical verification and validation supported the 510(k). An independent hospital study found generally close agreement between measured data and RayStation's VMC++ electron Monte Carlo calculations, but did not report the software version and did not assess clinical outcomes.
  • Public source
  • Product family
  • Checked 2026-09-02
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Electron output factors within 3% of measurement

141 of 170 output factors

  • EndpointCalculated output factors within plus or minus 3% of measured values
  • PopulationWater-tank and clinically relevant electron-beam geometries across 6 to 18 MeV
  • Tested versionRayStation VMC++ electron Monte Carlo; software release not reported

Electron output factors within 5% of measurement

164 of 170 output factors

  • EndpointCalculated output factors within plus or minus 5% of measured values
  • PopulationWater-tank and clinically relevant electron-beam geometries across 6 to 18 MeV
  • Tested versionRayStation VMC++ electron Monte Carlo; software release not reported

K190387 manufacturer software verification and validation

  • DesignManufacturer nonclinical software verification and validation supporting substantial equivalence
  • PopulationSoftware requirements, risk controls, treatment-planning functions, and changed functionality; no patient cohort reported
  • Scopeexact submission
  • Tested versionRayStation 8.1 / RayStation 8B cleared in K190387
  • IndependenceSponsor or vendor study

K190387

The FDA summary does not report an independent clinical performance or patient-outcomes study.

Evaluation of the RayStation electron Monte Carlo dose calculation algorithm

  • DesignIndependent single-center dosimetric validation against measured percentage-depth-dose, profile, heterogeneity, oblique-incidence, and output-factor data
  • PopulationVarian TrueBeam electron beams from 6 to 18 MeV in water-tank and clinically relevant phantom geometries
  • Scopeproduct family
  • Tested versionRayStation VMC++ electron Monte Carlo; software release not reported
  • Samplen=170
  • Sites1
  • IndependenceIndependent study

PMID 31629601

The publication reports no conflict of interest. Product-family evidence is not proof of equivalence to the exact 8B build, local beam model, machine, or protocol.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
FDA recall Z-2488-2025 includes RayStation 8B and its first two service packs. DICOM objects exported through the RayGateway interface to Accuray iDMS were not guaranteed to receive unique SOP Instance and Series Instance UIDs. FDA lists the recall as open and classified. FDA recall Z-1186-2025 includes RayStation 8B and its first two service packs. It concerns inconsistent interpretation of density uncertainty in robust optimization, robust evaluation, and perturbed-dose calculations for proton and light-ion plans using an HU-to-mass-density calibration curve. FDA lists the recall as open and classified. FDA recall Z-1743-2024 affects RayStation 8B builds 8.1.0.47, 8.1.1.8, and 8.1.2.5 because the reported source-to-surface distance could be too high. FDA lists the recall as open and classified. FDA recall Z-1482-2024 includes RayStation 8B. It addresses a use error in which elemental silicon could be selected instead of silicone gel polymer as an implant material override, with potentially greater consequence for ion-beam planning. FDA lists the recall as open and classified. FDA recall Z-2426-2020 includes RayStation 8B and concerns treatment-record handling with RayCare PACS and RayTreat, including manual-import propagation and display of planned versus delivered gantry angles. FDA lists the recall as open and classified. FDA recall Z-2346-2020 affected RayStation 8B because a pencil-beam or line-scanning dose-calculation error could locally underestimate expected dose. FDA lists the recall as terminated. FDA recall Z-2347-2020 affected RayStation 8B SP1 because a pencil-beam or line-scanning dose-calculation error could locally underestimate expected dose. FDA lists the recall as terminated. FDA recall Z-2348-2020 affected RayStation 8B SP2 because a pencil-beam or line-scanning dose-calculation error could locally underestimate expected dose. FDA lists the recall as terminated. FDA recall Z-1598-2020 includes RayStation 8.1 and concerns Siemens Virtual Wedge fields whose opening could exceed the treatment-machine vendor recommendation, potentially producing a high-dose plateau. FDA lists the recall as open and classified. FDA recall Z-1464-2020 affected RayStation or RayPlan 8B build 8.1.0.47 because tabletop positions could propagate incorrectly when pitch or roll correction was applied. FDA lists the recall as terminated. FDA recall Z-1465-2020 affected RayStation or RayPlan 8B SP1 build 8.1.1.8 because tabletop positions could propagate incorrectly when pitch or roll correction was applied. FDA lists the recall as terminated. FDA recall Z-1466-2020 affected RayStation or RayPlan 8B SP2 build 8.1.2.5 because tabletop positions could propagate incorrectly when pitch or roll correction was applied. FDA lists the recall as terminated. FDA recall Z-0866-2020 includes RayStation 8.1 and addresses three issues involving ROI mapping geometry, Elekta guard-leaf interoperability, and source-to-surface-distance handling. FDA lists the recall as terminated. FDA recall Z-0736-2020 includes RayStation 8.1 because editing a static arc beam could reset monitor units to the default 200 MU, requiring dose recalculation before approval or export. FDA lists the recall as terminated.
  • FDA source
  • Exact product version
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-2488-2025

Open, Classified

2025-09-02

The FDA record names RayStation 8B versions 8.1.0.47, 8.1.1.8, and 8.1.2.5. Sites should verify installed versions and the vendor correction or re-export workaround.

recall: Z-1186-2025

Open, Classified

2025-02-19

The FDA record explicitly names the RayStation 8B builds. Applicability depends on particle planning and the installed CT calibration approach.

recall: Z-1743-2024

Open, Classified

2024-05-01

Exact 8B build match. The FDA action directs users to verify critical SSD values with the Measure Tool and follow the vendor correction.

recall: Z-1482-2024

Open, Classified

2024-04-05

RayStation 8B is explicitly included. Sites should verify material-assignment review controls and whether the affected material remains available in the installed release.

recall: Z-2426-2020

Open, Classified

2020-05-26

The FDA record includes RayStation 8B. Exposure depends on RayCare or RayTreat use and the affected treatment-record workflow.

recall: Z-2346-2020

Terminated

2020-05-18

Exact RayStation 8B match. The FDA action described Monte Carlo or geometry-related workarounds; verify correction status and local particle-planning exposure.

recall: Z-2347-2020

Terminated

2020-05-18

Exact RayStation 8B SP1 match. Verify correction status and whether affected particle dose engines were used locally.

recall: Z-2348-2020

Terminated

2020-05-18

Exact RayStation 8B SP2 match. Verify correction status and whether affected particle dose engines were used locally.

recall: Z-1598-2020

Open, Classified

2020-03-04

The FDA record includes model 8.1. Applicability depends on Siemens Virtual Wedge planning and machine configuration.

recall: Z-1464-2020

Terminated

2020-02-20

Exact RayStation 8B build match. Verify installed build, correction status, and any six-degree-of-freedom setup workflow.

recall: Z-1465-2020

Terminated

2020-02-20

Exact RayStation 8B SP1 build match. Verify installed build, correction status, and any six-degree-of-freedom setup workflow.

recall: Z-1466-2020

Terminated

2020-02-20

Exact RayStation 8B SP2 build match. Verify installed build, correction status, and any six-degree-of-freedom setup workflow.

recall: Z-0866-2020

Terminated

2020-01-27

The FDA record includes model 8.1. Local exposure depends on the ROI, Elekta, and SSD workflows described in the correction.

recall: Z-0736-2020

Terminated

2019-11-18

The FDA record includes model 8.1. Verify installed correction status and plan-review controls for static arc beam edits.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
No public price for RayStation 8B was found. A 2025 vendor announcement reports a RMB 51 million RayStation order including a service contract for a Chinese carbon-ion center; this is a product-family, bundled institutional benchmark and is not an 8B list price or a transferable quote.
  • Product family
  • Checked 2026-09-02

Pricing context

These observations are not an exact-product procurement quotation. They are family, vendor, patient-charge, reimbursement, model, or unscoped records and are not comparable across dates, bundles, currencies, or units.

CNY 51000000

Price observation, scope not stated · total order including service contract · China

Observed 2025-03-04

Vendor-announced product-family order for a carbon-ion center. It is not a RayStation 8B list price, excludes unknown allocation across licenses and services, and should not be transferred to another institution or configuration.

Reimbursement

Reimbursement
CMS describes payment for professional and technical radiation therapy services, not a separate payment assigned to named treatment-planning software. The reviewed source does not support treating RayStation as independently reimbursed; local payer, contract, and service-line analysis remains necessary.
  • Service-level, not product-specific
  • Checked 2026-09-02

No product-specific code

No separate named-product payment identified in the reviewed CMS Radiation Oncology Model page

Medicare · United States

This is payment context for radiation therapy services, not a comprehensive coding or coverage determination.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Patient CT data and, where used, registered PET or MR images; user-defined regions of interest, treatment-machine data, prescription and optimization objectives, and other planning parameters.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-02 · K190387 FDA decision source

  2. Routing

    Source context, not route validation: The FDA summary describes DICOM import of CT images, multimodality registration with PET and MR, interfacing with a treatment console, and DICOM export of approved plans, dose, structures, and images to a DICOM server.

    Scope: Exact FDA submission. Confirm exact supported DICOM services, treatment-machine interfaces, transfer checks, interface ownership, and installed service-pack compatibility during local validation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-02 · K190387 FDA decision source

  3. AI processing

    Source context, not route validation: Software treatment-planning system deployed in the radiation oncology technical environment and connected to imaging, DICOM storage, and treatment-delivery workflows configured by the institution.

    Scope: Exact FDA submission. The reviewed FDA summary does not specify a transferable hardware, server, database, virtualization, or high-availability architecture for every 8B installation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-02 · K190387 FDA decision source

  4. Returned objects

    Source context, not route validation: Reviewed treatment plans, calculated dose distributions, structures, images, setup parameters, two- and three-dimensional plan displays, and dose-volume histograms; approved DICOM treatment objects can be exported for downstream use.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-02 · K190387 FDA decision source

  5. Viewer/worklist/report

    Unresolved route: Reviewed treatment plans, calculated dose distributions, structures, images, setup parameters, two- and three-dimensional plan displays, and dose-volume histograms; approved DICOM treatment objects can be exported for downstream use.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-02 · K190387 FDA decision source

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software treatment-planning system deployed in the radiation oncology technical environment and connected to imaging, DICOM storage, and treatment-delivery workflows configured by the institution.
  • Exact FDA submission
  • Checked 2026-09-02

The reviewed FDA summary does not specify a transferable hardware, server, database, virtualization, or high-availability architecture for every 8B installation.

Integration
The FDA summary describes DICOM import of CT images, multimodality registration with PET and MR, interfacing with a treatment console, and DICOM export of approved plans, dose, structures, and images to a DICOM server.
  • Exact FDA submission
  • Checked 2026-09-02

Confirm exact supported DICOM services, treatment-machine interfaces, transfer checks, interface ownership, and installed service-pack compatibility during local validation.

Training
The FDA-cleared intended-user statement requires clinically qualified radiation therapy staff who are appropriately trained in system use.
  • Exact FDA submission
  • Checked 2026-09-02

Procurement should define role-based training, competency assessment, commissioning privileges, plan-approval privileges, service-pack retraining, and support escalation.

DICOM planning workflow

Imports CT, supports PET and MR registration, and exports approved plans, dose, structures, and images to a DICOM server after plan review.

exact submission · checked 2026-09-02

Perform conformance review and end-to-end testing for every scanner, PACS, oncology information system, treatment console, and transfer path.

Planning and AI-assisted functions

The FDA summary describes contouring, image fusion, collapsed-cone dose calculation, four-dimensional compatibility, optimization, dose tracking and adaptation, deformable registration, machine-learning planning, and machine-learning segmentation.

exact submission · checked 2026-09-02

License, commissioning, validation, user privileges, and clinical scope should be mapped function by function; inclusion in the clearance summary does not mean every site has every option enabled.

Current product-family context

RaySearch continues to market RayStation as a configurable treatment-planning platform spanning multiple treatment techniques and machine ecosystems.

product family · checked 2026-09-02

Current product-family features, hardware requirements, cybersecurity controls, and commercial terms must not be assumed to apply to an installed 8B release.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K190387
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-02
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-06-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
22Fields reviewed
10Source classes checked
20Awaiting review PubMed leads
5Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. The exact FDA summary, current vendor product context, peer-reviewed product-family dosimetry evidence, public pricing observation, CMS payment context, and every exact-identifier FDA recall candidate were manually reviewed. Security and operational-monitoring details remain explicitly unresolved for the exact 8B release rather than being inferred from later documentation. Automated exact-name discovery found 20 PubMed and 5 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 32 FDA recall candidates were manually reviewed: 14 published and 18 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 32 postmarket candidate records; 32 have been reviewed (14 published, 18 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, peer reviewed publication, vendor product page, vendor pricing observation, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-02 - Exact product version

    No exact RayStation 8B cybersecurity architecture or supported-platform security guide was established from the reviewed public sources. Obtain the version-specific security, patching, identity, encryption, audit, remote-access, backup, and vulnerability-management documentation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not publicly available - checked 2026-09-02 - Exact product version

    The reviewed public sources do not define an exact 8B operational monitoring program. Require local dose-calculation commissioning, end-to-end testing, DICOM transfer checks, machine and beam-model change control, backup testing, service-pack regression testing, incident review, and recall surveillance.

24 sources - 2 history items

Source ledger

  1. K190387 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-2488-2025: RayStation with the following product descriptions: 1. RayStation 8B, Software Version: 8.1.0.47. 2. RayStation 8B Service Pack 1, Software Version: 8.1.1.8. 3. RayStation 8B Service Pack 2, Software Version: 8.1.2.5. 4. RayStation 9A, Software Version: 9.0.0.113. 5. RayStation 9A Service Pack 1, Software Version: 9.0.1.142. Product Description: Radiation Therapy Treatment Planning System.

    U.S. Food and Drug Administration - Published 2025-09-02 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-1186-2025: Brand Name: RayStation -Intended as a Radiation Therapy Treatment Planning System Model/Catalog Number: 8.1.0.47, 8.1.1.8, 8.1.2.5, 9.0.0.113 and 9.0.1.142 Software Version: RayStation 8B, 8B Service Pack 1 and 2, 9A and 9A Service Pack 1

    U.S. Food and Drug Administration - Published 2025-02-19 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. FDA recall Z-1743-2024: RayStation 8.1.0.47, 8.1.1.8 and 8.1.2.5. Radiation Therapy Treatment Planning System.

    U.S. Food and Drug Administration - Published 2024-05-01 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  6. FDA recall Z-1482-2024: RayStation Software Version Numbers version numbers 8B, 9A, 9B, 10A, 10B, 11A, 11B, 12A, 12B, 2023B, 2024A including some service packs.

    U.S. Food and Drug Administration - Published 2024-04-05 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  7. FDA recall Z-2426-2020: RayStation standalone software treatment planning system (RayStation 8A, 8B, 9A, and 9B, including all service packs) model no. 8.0, 8.1, 9.0, 9.1, 9.2

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  8. FDA recall Z-2346-2020: RayStation 8B, UDI # 07350002010129 - Product Usage: For radiation therapy and medical oncology which can also be used to administer treatments.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  9. FDA recall Z-2347-2020: RayStation 8B Service Pack 1, UDI # 07350002010204 - Product Usage: For radiation therapy and medical oncology which can also be used to administer treatments.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  10. FDA recall Z-2348-2020: RayStation 8B Service Pack 2, UDI # 07350002010235 - Product Usage: For radiation therapy and medical oncology which can also be used to administer treatments.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  11. FDA recall Z-1598-2020: RayStation standalone software treatment planning system, Model Numbers 4.0, 4.5, 4.7, 4.9, 5.0, 6.0, 7.0, 8.0, 8.1, 9.0, 9.1 - Product Usage: RayStation is a software system for radiation therapy and medical oncology. Based on user input, RayStation proposes treatment plans. After a proposed treatment plan is reviewed and approved by authorized intended users, RayStation may also be used to administer treatments. The system functionality can be configured based on user needs.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  12. FDA recall Z-1464-2020: RayStation/RayPlan 8B, Build Number 8.1.0.47, stand-alone software treatment planning system

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  13. FDA recall Z-1465-2020: RayStation/RayPlan 8B Service Pack 1, Build Number 8.1.1.8, stand-alone software treatment planning system

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  14. FDA recall Z-1466-2020: RayStation/RayPlan 8B Service Pack 2, Build Number 8.1.2.5, stand-alone software treatment planning system

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  15. FDA recall Z-0866-2020: RayStation stand-alone software treatment planning system. Models 4.0, 4.3, 4.5, 4.7, 4.9, 5.0, 6.0, 6.1, 6.2, 6.3, 7.0, 8.0, 8.1, 9.0.

    U.S. Food and Drug Administration - Published 2020-01-27 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  16. FDA recall Z-0736-2020: RayStation stand-alone software treatment planning system, Model Numbers 4.0, 4.5, 4.7, 4.9, 5.0, 6.0, 6.1, 6.2, 6.3, 7.0, 8.0, 8.1, 9.0 - Product Usage: RayStation is a software system designed for treatment planning and analysis of radiation therapy. The treatment plans provide treatment unit set-up parameters and estimates of dose distributions expected during the proposed treatment, and may be used to administer treatments after review and approval by the intended user. The system functionality can be configured based on user needs. The intended users of RayStation shall be clinically qualified radiation therapy staff trained in using the system.

    U.S. Food and Drug Administration - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  17. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  18. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  19. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  20. RayStation treatment planning system product page

    RaySearch Laboratories - Accessed 2026-09-02

    Scope: productFamily, implementationCapabilities, currentCommercialContext

  21. RayStation safety and performance information

    RaySearch Laboratories - Accessed 2026-09-02

    Scope: instructionsForUse, releaseNotes, systemEnvironmentGuidelines

  22. Evaluation of the RayStation electron Monte Carlo dose calculation algorithm

    Medical Dosimetry - Published 2019-10-17 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics

  23. Heyou Hospital selects RayStation for its carbon-ion center

    RaySearch Laboratories - Published 2025-03-04 - Accessed 2026-09-02

    Scope: pricing, economicsObservation, productFamily

  24. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

Research history

  1. K190387 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242748

Oncospace

Oncospace, Inc.

Authorized purpose: Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review across head-and-neck, thoracic, abdominal, and pelvic workflows using locked models.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history